Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 46 of 151

  1. DRI19220

    Sanofi-aventis Healthcare Pty Ltd

    Hidradenitis suppurativa

    phase 2 other active

    1 trial

  2. DRUID AI Program

    Hospital Authority, Hong Kong

    Solid Organ Malignancies

    phase 2 other active

    1 trial

  3. DS-1062a

    Daiichi Sankyo

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  4. DS-3939a

    Daiichi Sankyo

    Metastatic Solid Tumor, Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  5. DS-5141b

    Daiichi Sankyo

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  6. DS-8201a

    Ningbo Cancer Hospital

    Metastatic Breast Cancer HR+, HER2-

    phase 2 small molecule active

    1 trial

  7. DS-8201a

    AstraZeneca AB

    HER2 Expressing Tumors

    phase 2 small molecule active

    1 trial

  8. DS-8201a

    AstraZeneca AB

    Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology

    phase 2 small molecule active

    1 trial

  9. DS-8201a

    Daiichi Sankyo

    Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer

    phase 2 small molecule active

    1 trial

  10. DS3201-330

    Daiichi Sankyo

    Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  11. DS7300-189

    Daiichi Sankyo

    Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  12. DSC/11/2357/44

    Italfarmaco S.p.A.

    Chronic myeloproliferative neoplasm

    phase 2 small molecule active

    1 trial

  13. DSM265

    CNS Pharmaceuticals

    Malaria

    phase 2 small molecule terminated

    2 trials

  14. DT-168

    Lxo Ireland Designated Activity Company

    Fuchs Endothelial Corneal Dystrophy

    phase 2 small molecule active

    1 trial

  15. DT-216P2

    Lxo Ireland Designated Activity Company

    Friedreich Ataxia

    phase 2 small molecule active

    2 trials

  16. DT-DEC01

    Wuhan Createrna Science and Technology Co., Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  17. DTPw-HBV/Hib-MenAC conjugate vaccine

    GlaxoSmithKline

    Diphtheria

    phase 2 mab completed

    1 trial

  18. DTX101

    Ultragenyx UK Limited

    Hemophilia B

    phase 2 gene therapy terminated

    1 trial

  19. DTX401

    Ultragenyx UK Limited

    GSD1

    phase 2 gene therapy completed

    1 trial

  20. DUO2022_01

    Lacuna Pharma Pty Ltd

    Surgical wound infection/dehiscence caused by S. aureus and/or P. aeruginosa colonization

    phase 2 small molecule active

    1 trial

  21. DURVALUMAB

    Fondazione Telethon ETS

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. DURVALUMAB, Ceralasertib

    Istituto Gentili S.r.l.

    Stage III NSCLC patients with loco-regional relapse > 12 months from the end of CRT +/- < 3 metastatic lesions after PACIFIC regimen or PACIFIC-like regimens (concurrent or sequential chemo-radiotherapy followed by maintenance durvalumab), regardless of PD-L1 status, but without EGFR, HER-2 or MET exon14 skipping mutations, ALK, ROS1, RET or NTRK rearrangements.

    phase 2 small molecule active

    1 trial

  23. DX-88 (ecallantide)

    Takeda

    Hereditary Angioedema (HAE)

    phase 2 small molecule completed

    1 trial

  24. DYNE-101

    Dyne Therapeutics

    Myotonic Dystrophy Type 1 (DM1)

    phase 2 small molecule active

    1 trial

  25. DYNE-101 for Myotonic Dystrophy Type 1

    Dyne Therapeutics

    Myotonic Dystrophy Type 1

    phase 2 small molecule active

    1 trial

  26. DYNE-251

    Dyne Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  27. DYNE251-DMD-201

    Dyne Therapeutics

    Duchenne muscular dystrophy

    phase 2 small molecule active

    1 trial

  28. DYP688

    Novartis Pharmaceuticals

    Metastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)

    phase 2 small molecule active

    1 trial

  29. Dabogratinib (TYRA-300) 60mg

    Tyra Biosciences

    Low Grade Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  30. Dabrafenib

    Novartis Pharmaceuticals

    Cancer

    phase 2 small molecule completed

    1 trial

  31. Dalpiciclib

    The First People's Hospital of Lianyungang

    Early Breast Cancer

    phase 2 small molecule active

    1 trial

  32. Danavorexton

    Takeda

    Sleep Apnea

    phase 2 small molecule completed

    2 trials

  33. Danggui Buxue Tang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  34. Dapagliflozin 10mg Tab

    The University of Hong Kong

    Lupus Nephritis

    phase 2 small molecule active

    1 trial

  35. Daptomycin for Injection

    Merck KGaA, Darmstadt, Germany

    Bacteremia

    phase 2 small molecule completed

    1 trial

  36. Daratumumab Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    2 trials

  37. Daraxonrasib

    Revolution Medicines

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  38. Darinaparsin

    Alaunos Therapeutics

    Hematologic Neoplasms

    phase 2 small molecule completed

    1 trial

  39. Darinaparsin

    Alaunos Therapeutics

    HEPATOCELLULAR CARCINOMA

    phase 2 small molecule active

    1 trial

  40. Darinaparson

    Alaunos Therapeutics

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  41. Darleukin, Fibromun

    Philogen S.p.A.

    Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.

    phase 2 small molecule active

    1 trial

  42. Darleukin, Fibromun

    Philogen S.p.A.

    locally advanced basal cell carcinoma patients

    phase 2 small molecule active

    1 trial

  43. Darolutamide+ADT

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  44. Darovasertib

    Hospital Authority, Hong Kong

    Ocular Melanoma

    phase 2 small molecule completed

    1 trial

  45. Dasatinib

    Takeda

    Acute Lymphoblastic Leukemia

    phase 2 small molecule terminated

    1 trial

  46. Dasatinib

    Bristol-Myers Squibb

    Chronic Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  47. Datopotamab deruxtecan

    Daiichi Sankyo

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  48. Datopotamab deruxtecan

    AstraZeneca AB

    Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.